During the last three months, 7 analysts shared their evaluations of Arcturus Therapeutics (NASDAQ:ARCT), revealing diverse outlooks from bullish to bearish. The following table summarizes their ...
Arcturus Therapeutics is transitioning from COVID-era revenues to milestone-driven growth. Click here to read more on ARCT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback